CL2020000056A1 - Nuevos derivados de xantina sustituidos. - Google Patents

Nuevos derivados de xantina sustituidos.

Info

Publication number
CL2020000056A1
CL2020000056A1 CL2020000056A CL2020000056A CL2020000056A1 CL 2020000056 A1 CL2020000056 A1 CL 2020000056A1 CL 2020000056 A CL2020000056 A CL 2020000056A CL 2020000056 A CL2020000056 A CL 2020000056A CL 2020000056 A1 CL2020000056 A1 CL 2020000056A1
Authority
CL
Chile
Prior art keywords
xanthine derivatives
substituted xanthine
new substituted
derivatives
trpc5
Prior art date
Application number
CL2020000056A
Other languages
English (en)
Inventor
Kai Gerlach
Christian Eickmaier
Achim Sauer
Stefan Just
Bertrand L Chenard
Original Assignee
Hydra Biosciences Llc
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hydra Biosciences Llc, Boehringer Ingelheim Int filed Critical Hydra Biosciences Llc
Publication of CL2020000056A1 publication Critical patent/CL2020000056A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS DE XANTINA SUSTITUIDOS, A COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y A SU USO EN TERAPIA, PARTICULARMENTE EN EL TRATAMIENTO DE ESTADOS QUE TIENEN UNA ASOCIACIÓN CON CANALES IÓNICOS QUE CONTIENEN TRPC5.
CL2020000056A 2017-07-11 2020-01-08 Nuevos derivados de xantina sustituidos. CL2020000056A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17180721 2017-07-11

Publications (1)

Publication Number Publication Date
CL2020000056A1 true CL2020000056A1 (es) 2020-06-12

Family

ID=59325162

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000056A CL2020000056A1 (es) 2017-07-11 2020-01-08 Nuevos derivados de xantina sustituidos.

Country Status (30)

Country Link
US (1) US10329292B2 (es)
EP (1) EP3652176B1 (es)
JP (1) JP7114702B2 (es)
KR (1) KR20200030048A (es)
CN (1) CN110997675B (es)
AR (1) AR112448A1 (es)
AU (1) AU2018299824B2 (es)
BR (1) BR112019025611A2 (es)
CA (1) CA3066922A1 (es)
CL (1) CL2020000056A1 (es)
CO (1) CO2019015102A2 (es)
CY (1) CY1125014T1 (es)
DK (1) DK3652176T3 (es)
EA (1) EA039526B1 (es)
ES (1) ES2903268T3 (es)
HR (1) HRP20220029T1 (es)
HU (1) HUE057600T2 (es)
IL (1) IL271799B (es)
LT (1) LT3652176T (es)
MX (1) MX2020000402A (es)
PH (1) PH12020500079A1 (es)
PL (1) PL3652176T3 (es)
PT (1) PT3652176T (es)
RS (1) RS62826B1 (es)
SA (1) SA519410851B1 (es)
SG (1) SG11201912168TA (es)
SI (1) SI3652176T1 (es)
TW (1) TWI801398B (es)
UA (1) UA124793C2 (es)
WO (1) WO2019011802A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166150B (zh) * 2018-12-12 2023-12-01 勃林格殷格翰国际有限公司 经取代的黄嘌呤衍生物
KR20210102955A (ko) * 2018-12-12 2021-08-20 베링거 인겔하임 인터내셔날 게엠베하 치환된 크산틴 유도체
JP2022551580A (ja) * 2019-10-04 2022-12-12 ゴールドフィンチ バイオ，インク． 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ528216A (en) * 2001-02-24 2006-12-22 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
ATE496894T1 (de) * 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
JP6360149B2 (ja) * 2013-03-15 2018-07-18 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 置換キサンチンおよびその使用方法
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
WO2016023830A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
WO2016023831A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
JP6559228B2 (ja) 2014-09-17 2019-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症及び糖尿病の治療に有用なテトラヒドロイソキノリン誘導体及び医薬組成物

Also Published As

Publication number Publication date
EP3652176A1 (en) 2020-05-20
CY1125014T1 (el) 2023-03-24
CA3066922A1 (en) 2019-01-17
MX2020000402A (es) 2020-08-17
BR112019025611A2 (pt) 2020-06-16
ES2903268T3 (es) 2022-03-31
DK3652176T3 (da) 2022-01-17
CN110997675B (zh) 2022-06-07
SI3652176T1 (sl) 2022-04-29
US20190016722A1 (en) 2019-01-17
IL271799B (en) 2022-08-01
UA124793C2 (uk) 2021-11-17
HRP20220029T1 (hr) 2022-04-15
EP3652176B1 (en) 2021-12-15
CN110997675A (zh) 2020-04-10
AU2018299824A1 (en) 2019-12-19
TW201908318A (zh) 2019-03-01
RS62826B1 (sr) 2022-02-28
US10329292B2 (en) 2019-06-25
HUE057600T2 (hu) 2022-05-28
PT3652176T (pt) 2022-01-13
JP2020526591A (ja) 2020-08-31
EA202090270A1 (ru) 2020-04-24
IL271799A (en) 2020-02-27
EA039526B1 (ru) 2022-02-07
AR112448A1 (es) 2019-10-30
KR20200030048A (ko) 2020-03-19
CO2019015102A2 (es) 2020-05-15
PH12020500079A1 (en) 2020-10-05
TWI801398B (zh) 2023-05-11
PL3652176T3 (pl) 2022-04-04
SG11201912168TA (en) 2020-01-30
WO2019011802A1 (en) 2019-01-17
AU2018299824B2 (en) 2022-06-16
JP7114702B2 (ja) 2022-08-08
LT3652176T (lt) 2022-02-25
SA519410851B1 (ar) 2023-02-26

Similar Documents

Publication Publication Date Title
CO2017001994A2 (es) Compuestos activos hacia bromodominios
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
SV2018005778A (es) Derivados aromaticos de sulfonamida
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
CR20180320A (es) Compuestos inhibidores de la quinasa de union a tank
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2016000925A1 (es) Inhibidores de bromodominio
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2016001364A1 (es) Moduladores de ror gamma (rory)
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
BR112016025787A2 (pt) Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
CL2018003417A1 (es) Nuevos compuestos.
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
CO2018008445A2 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-deca
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica